Truist Cuts PT on Stryker Corporation (SYK) as Part of Fiscal Q1 Results Preview in MedTech

Stryker Corporation (NYSE:SYK) is one of the best medical device stocks to invest in right now. Truist cut the price target on Stryker Corporation (NYSE:SYK) to $380 from $395 on April 15, reaffirming a Hold rating on the shares. The rating update came as part of a broader research note previewing fiscal Q1 results in MedTech, with the firm stating that it anticipates fiscal Q1 performances to be in line or better than what feels like an anxious investor sentiment around Q1 volumes. It further stated in a research note that a premium valuation is justified for the stock given its view of the company’s high-quality, above-average revenue growth profile. However, it also prefers to have higher conviction in EPS upside and faster earnings growth potential.

Stryker (SYK) Expands Digital Healthcare Push with New SmartHospital Platform

Stryker Corporation (NYSE:SYK) also received a rating update from BTIG on April 13. The firm lowered the price target on the stock to $397 from $412 and maintained a Buy rating on the shares. The rating update came as part of a broader research name on Medical Technology.

Stryker Corporation (NYSE:SYK) is a medical technology company that offers products and services that help improve patient and health outcomes. Its operations are divided into the MedSurg and Neurotechnology and the Orthopedics and Spine segments.

While we acknowledge the risk and potential of SYK as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than SYK and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey on Google News.